is being presented by Todd Wulffson, Employment Counsel, with Greenberg Traurig, LLP and airs on Wednesday, November 16th, 2011. For more details or to register, please visit our site at www.fxconferences.com
Social Media has become a true cultural phenomenon. Companies of all sizes are taking advantage of social media to market their goods and services and expand their revenue base. However, social media also brings with it new, and in many cases, unknown liability issues. Companies are being held accountable for the activity of employees on social media – regardless of whether the company is specifically aware of that activity – and FTC guidelines can impose liability for activities by employee endorsers and affiliate marketers if the company does not exercise appropriate supervision. This audio conference presentation is specifically designed to provide HR and in-house counsel with the ability to recognize potential threats and take action proactively before liability arises.
Showing posts with label liability. Show all posts
Showing posts with label liability. Show all posts
Thursday, November 3, 2011
Thursday, October 29, 2009
Developing a Post-Approval Labeling Risk Management Strategy
Patient injured because of event described in black box warning: Company still liable, long established FDA approved warnings not sufficient...
Patient injured on generic drug: innovator company could be liable for inadequate warnings...
FDA-approved labeling is no longer a regulatory and liability safe zone. Companies face rapidly escalating FDA, product, reimbursement and patent liabilities tied to labeling management. Penalties, damages and fines are hitting billion-dollar-plus levels, with consideration of direct liability for executives being openly discussed. Traditional labeling development and management approaches that center on FDA approval and adverse event reporting are not up to the task of protecting companies and their executives. This audio conference explains what has happened over the last year and likely changes for the coming years and what to do now to position products for success and avoid liability or regulatory disaster.
Developing a Post-Approval Labeling Risk Management Strategy is being presented by Gary Gamerman, President, of Seraphim Life Sciences Consulting LLC and airs on Tuesday, December 1, 2009. For more details or to register, please visit our site at www.fxconferences.com
Patient injured on generic drug: innovator company could be liable for inadequate warnings...
FDA-approved labeling is no longer a regulatory and liability safe zone. Companies face rapidly escalating FDA, product, reimbursement and patent liabilities tied to labeling management. Penalties, damages and fines are hitting billion-dollar-plus levels, with consideration of direct liability for executives being openly discussed. Traditional labeling development and management approaches that center on FDA approval and adverse event reporting are not up to the task of protecting companies and their executives. This audio conference explains what has happened over the last year and likely changes for the coming years and what to do now to position products for success and avoid liability or regulatory disaster.
Developing a Post-Approval Labeling Risk Management Strategy is being presented by Gary Gamerman, President, of Seraphim Life Sciences Consulting LLC and airs on Tuesday, December 1, 2009. For more details or to register, please visit our site at www.fxconferences.com
Subscribe to:
Posts (Atom)